down arrow

Denali Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US24823R1059
USD
20.11
2.27 (12.72%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

18.5520.48

52 Week

10.5726.18
Valuation
Technical
Day's Volume

CASH

795.34 k

Shareholding (Mar 2025)

FII

31.99%

Held by 141 FIIs

DII

21.94%

Held by 57 DIIs

Promoter

5.54%

How big is Denali Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Denali Therapeutics, Inc. has a market capitalization of $2,035.32 million, with net sales of $0.00 million and a net profit of -$453.94 million over the latest four quarters. The company reported shareholder's funds of $1,229.68 million and total assets of $1,374.18 million as of Dec'24.

Market Cap: As of Jun 18, Denali Therapeutics, Inc. has a market capitalization of 2,035.32 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Denali Therapeutics reported net sales of 0.00 million and a net profit of -453.94 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 1,229.68 million and total assets of 1,374.18 million.

Read More

What does Denali Therapeutics, Inc. do?

22-Jun-2025

Denali Therapeutics, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases, with a market cap of approximately $2.04 billion and a recent net profit of -$133 million. The company has no dividend yield and is currently loss-making.

Overview:<BR>Denali Therapeutics, Inc. is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -133 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 2,035.32 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.72<BR>Return on Equity: -40.43%<BR>Price to Book: 1.81<BR><BR>Contact Details:<BR>Address: 161 Oyster Point Blvd, SOUTH SAN FRANCISCO CA: 94080-1910<BR>Tel: 1 650 8668548<BR>Fax: 1 302 6555049<BR>Website: https://www.denalitherapeutics.com

Read More

Who are in the management team of Denali Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Denali Therapeutics, Inc.'s management team includes Dr. Vicki Sato (Independent Chairman), Mr. Ryan Watts (President and CEO), and several independent directors: Ms. Nancy Thornberry, Mr. Douglas Cole, Ms. Jennifer Cook, Mr. Jay Flatley, and Mr. Peter Klein. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Denali Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Vicki Sato, who serves as the Independent Chairman of the Board.<BR>- Mr. Ryan Watts, who is the President, Chief Executive Officer, Co-Founder, and Director.<BR>- Ms. Nancy Thornberry, who is a Director.<BR>- Mr. Douglas Cole, who is an Independent Director.<BR>- Ms. Jennifer Cook, who is an Independent Director.<BR>- Mr. Jay Flatley, who is an Independent Director.<BR>- Mr. Peter Klein, who is an Independent Director.<BR><BR>This team is responsible for guiding the company’s strategic direction and operations.

Read More

Is Denali Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of November 6, 2024, Denali Therapeutics, Inc. is overvalued and has deteriorated to a "does not qualify" rating due to negative financial metrics and a year-to-date return of -33.17%, significantly underperforming compared to its peers and the S&P 500.

As of 6 November 2024, Denali Therapeutics, Inc. has moved from a valuation grade of risky to does not qualify, indicating a significant deterioration in its financial health. The company is currently overvalued, with a Price to Book Value of 1.90 and negative ratios such as EV to EBIT at -2.57 and EV to EBITDA at -2.61, reflecting ongoing losses and a lack of profitability. <BR><BR>In comparison to its peers, Denali's valuation metrics are concerning; for instance, Axsome Therapeutics, Inc. has a P/E ratio of -20.23, while Krystal Biotech, Inc. is considered expensive with a P/E of 25.47. The company's recent performance has also lagged behind broader market indices, with a year-to-date return of -33.17% compared to the S&P 500's gain of 2.44%. Overall, Denali Therapeutics appears to be overvalued given its financial indicators and relative position within its industry.

Read More

Is Denali Therapeutics, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Denali Therapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 with a year-to-date return of -25.32% compared to the S&P's 14.18%.

As of 3 October 2025, the technical trend for Denali Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators including a mildly bullish MACD on the weekly timeframe, but bearish on the monthly. The daily moving averages indicate a mildly bearish trend, while Bollinger Bands show a mildly bullish signal weekly but mildly bearish monthly. The KST is bullish weekly but bearish monthly, and the OBV is mildly bullish monthly. <BR><BR>In terms of performance, Denali has underperformed the S&P 500 across multiple periods, with a year-to-date return of -25.32% compared to the S&P's 14.18%, and a one-year return of -46.84% versus 17.82% for the index.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,266 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.87

stock-summary
Return on Equity

-46.64%

stock-summary
Price to Book

2.21

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-124 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
31.35%
0%
31.35%
6 Months
44.36%
0%
44.36%
1 Year
-15.82%
0%
-15.82%
2 Years
6.01%
0%
6.01%
3 Years
-38.37%
0%
-38.37%
4 Years
-52.78%
0%
-52.78%
5 Years
-69.64%
0%
-69.64%

Denali Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Denali Therapeutics, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Denali Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators including a mildly bullish MACD on the weekly timeframe, but bearish on the monthly. The daily moving averages indicate a mildly bearish trend, while Bollinger Bands show a mildly bullish signal weekly but mildly bearish monthly. The KST is bullish weekly but bearish monthly, and the OBV is mildly bullish monthly. In terms of performance, Denali has underperformed the S&P 500 across multiple periods, with a year-to-date return of -25.32% compared to the S&P's 14.18%, and a one-year return of -46.84% versus 17.82% for the index....

Read More

Is Denali Therapeutics, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Denali Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while the weekly MACD and KST show mild bullishness. The Bollinger Bands are bullish on the weekly timeframe but mildly bearish on the monthly. The overall strength is mixed, with the Dow Theory indicating a mildly bearish trend on the weekly. In terms of performance, Denali has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -24.34% versus the S&P 500's 14.18%, and a one-year return of -45.36% compared to 17.82% for the index....

Read More

Is Denali Therapeutics, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Denali Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend, while the weekly MACD and KST show mild bullishness. The Bollinger Bands on a weekly basis are bullish, but the monthly indicators suggest a bearish outlook. The stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -24.34% versus the S&P 500's 14.18%, and a one-year return of -45.36% compared to the S&P 500's 17.82%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-180.04%
EBIT to Interest (avg)
-271.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.72
Sales to Capital Employed (avg)
0.20
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
1.05%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.90
EV to EBIT
-2.57
EV to EBITDA
-2.61
EV to Capital Employed
4.23
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-164.42%
ROE (Latest)
-40.43%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 68 Schemes (40.5%)

Foreign Institutions

Held by 141 Foreign Institutions (31.99%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -25.35% vs -153.98% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-131.90",
          "val2": "-114.70",
          "chgp": "-15.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-124.10",
          "val2": "-99.00",
          "chgp": "-25.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 204.61% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -191.18% vs 55.46% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "330.50",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-494.10",
          "val2": "-180.00",
          "chgp": "-174.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-422.80",
          "val2": "-145.20",
          "chgp": "-191.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-595.10%",
          "chgp": "59.51%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-131.90
-114.70
-15.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-124.10
-99.00
-25.35%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -25.35% vs -153.98% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
330.50
-100.00%
Operating Profit (PBDIT) excl Other Income
-494.10
-180.00
-174.50%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-422.80
-145.20
-191.18%
Operating Profit Margin (Excl OI)
0.00%
-595.10%
59.51%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 204.61% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -191.18% vs 55.46% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Denali Therapeutics, Inc. stock-summary
stock-summary
Denali Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company’s development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.
Company Coordinates stock-summary
Company Details
161 Oyster Point Blvd , SOUTH SAN FRANCISCO CA : 94080-1910
stock-summary
Tel: 1 650 8668548
stock-summary
https://www.denalitherapeutics.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."